Immuno-Oncology

Immuno-oncology breakthroughs: from precision medicine to modulating the tumor microenvironment

The European Association for Cancer Research (EACR) explores the most exciting cancer research from Europe and globally. Clarivate Life Sciences Editor Joan Tur reviews the top three trends from their recent immuno-oncology event, and their implications for the future of cancer treatment. Despite pandemic-driven clinical trial delays across multiple therapy areas, novel immuno-oncology approaches continue […]

Diverse approaches in immuno-oncology

A fascinating range of insights into the ways in which the immune system can be harnessed to fight cancer was provided by Global Engage’s Immuno-Oncology Research & Technology Series meeting this month in London. The conference comprised five concurrent tracks covering cutting-edge developments in fields such as cell therapies, novel antibodies and neoantigens. Some of […]

Oncology landscape stays hot for dealmakers

Intense competition for dealmaking in oncology “shows no sign of abating.” That’s the key takeaway from recent analysis developed by Jamie Munro and Helen Dowden, of Clarivate Analytics. Their article, “Oncology dealmaking trends”, was featured in the Biopharma Dealmakers supplement to Nature Biotechnology and Nature Reviews: Drug Discovery. Munro, global practice leader, portfolio and licensing, […]

Immuno-oncology spotlight on diverse therapeutic classes

Immune checkpoint inhibitors, such as the multi-billion-dollar drugs Keytruda and Opdivo, have dominated the immuno-oncology landscape in recent years (see Figure 1), but are not the only classes on the market or in development. T-cell engager therapeutics, oncolytic virus therapy and adoptive T-cell therapies were among the promising technologies covered at the fourth annual Immuno-Oncology […]

European biotech on course for record year with $3.9B raised in first half of 2018

This is the second of a two-part series on Life Sciences Connect looking at the current robust financial climate for biopharma. “Biopharma IPOs gone wild,” also via BioWorld, the daily biopharma news service from Clarivate Analytics, appeared on July 10, 2018. European biotechnology firms engaged in drug development raised $3,904 million during the first half […]

Biopharma IPOs gone wild: Highest amount ever raised as 14 companies join public ranks

This is the first of a two-part series on “Life Sciences Connect” looking at the current robust financial climate for biopharma. Watch for a report, also via BioWorld, the daily biopharma news service from Clarivate Analytics, on the record pace of fund raising in Europe shortly. The public offerings by immuno-oncology-focused Forty Seven Inc., which […]

Women have their say as all-female panel talks biopharma investment, technology trends

This article is part of an ongoing series from Clarivate Analytics celebrating women in STEM with profiles of female scientists, inventors, researchers, and corporate leaders featured in BioWorld, Derwent, Web of Science, and Publons. See more articles in this series, or follow our online campaign using #WomenAtClarivate. One of the hottest tickets in town during […]

Oncology, driven by the promise of IO, dominates biopharma deals landscape

Spurred by the promise of immuno-oncology (IO), oncology dominated the biopharma dealmaking landscape last year, a new article by Jamie Munro and Helen Dowden, of Clarivate Analytics, shows. The acute interest in IO continues a trend, the article noted: The technology has been a factor in 32 of the 35 multibillion-dollar oncology licensing deals over […]

CAR T-cell gene therapies enter the U.S. market

Ground-breaking anti-cancer immunotherapy Novartis and the University of Pennsylvania’s anti-cancer chimeric antigen receptor (CAR) T-cell therapy Kymriah has become the first ever gene-modified therapy approved in the U.S. The therapy takes the patient’s own T cells, engineers them to express a receptor that binds to the B-cell blood cancer marker CD19, and then re-infuses them […]